Effect of silibinin on the hyperlipidemia in rats fed with high cholesterol diet
Abstract
Purpose: Despite current hypolipidemic drugs, the search for a more effective hypolipidemic agent is ongoing. In this study, it was aimed to investigate the effect of Silibinin on hyperlipidemia in rats fed high cholesterol diet (HCD).
Materials and Methods: Rats were made obese. Rats were given egg yolk for 60 days and then 50 mg/kg, 100 mg/kg Silibinin were applied i.p. for 7 days.
Results: The first and last weights of the rats were significantly different. While total cholesterol (TC), LDL, TG and VLDL levels increased significantly in the groups fed with HCD, HDL level reduced compared to control group (CG). OxLDL and TAS were significantly different between groups.
Conclusion: The effects of Silibinin on serum LDL, TC, VLDL, HDL, TG, OxLDL levels and to observe the antioxidant effect, TAS and TOS were investigated in experimental obese rat models. It was concluded that Silibinin plays an effective role in lowering TG and LDL levels, increasing HDL levels and decreasing hepatic lipid accumulation in HCD rats at 100 mg/kg dose. The use of Silibinin does not cause antihyperlipidemic effect but has antioxidant effect.
Kaynakça
- 1. Sun CJ, McCudden C, Brisson D, Shaw J, Gaudet D, Ooi TC. Calculated Non-HDL Cholesterol Includes Cholesterol in Larger Triglyceride-Rich Lipoproteins in Hypertriglyceridemia. J Endocr Soc. 2019; 3;4(1):bvz010.
- 2. Strilchuk L, Tocci G, Fogacci F, Cicero AFG. An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. Expert Opin Pharmacother. 2020; 21(5):531-539.
- 3. Sahle BW, Chen W, Melaku YA, Akombi BJ, Rawal LB, Renzaho AMN. Association of Psychosocial Factors with Risk of Chronic Diseases: A Nationwide Longitudinal Study. Am J Prev Med. 2020; 58(2):e39-e50.
- 4. Olivecrona G. Role of lipoprotein lipase in lipid metabolism. Current opinion in lipidology. 2016; 27(3):233-241.
- 5. Ossoli A, Simonelli S, Vitali C, Franceschini G, Calabresi L. Role of LCAT in Atherosclerosis. J Atheroscler Thromb. 2016; 23(2):119-27.
- 6. Wallace SN, Raible J, Carrier DJ, Vaughn KL, Griffis CL, Clausen EC, Nagarajan S. Pressurized water versus ethanol as a Silybum marianum extraction solvent for inhibition of low-density lipoprotein oxidation mediated by copper and J774 macrophage cells. Can J Physiol Pharmacol. 2007; 85, 894–902.
- 7. Tajmohammadi A, Razavi BM, Hosseinzadeh H. Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: A review. Phytother Res. 2018;32(10):1933-1949.
- 8. Kockx M, Traini M, Kritharides L. Cell-specific production, secretion, and function of apolipoprotein. E. J Mol Med (Berl). 2018; 96(5):361-371.
- 9. Sahebkar A, Simental-Mendía LE, Pirro M, Banach M, Watts GF, Sirtori C, Al-Rasadi K, Atkin SL. Author Correction: Impact of ezetimibe on plasma lipoprotein (a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2020; 10(1):2999.
- 10. Parashar P, Rana P, Dwivedi M, Saraf SA. Dextrose modified bilosomes for peroral delivery: improved therapeutic potential and stability of silymarin in diethylnitrosamine-induced hepatic carcinoma in rats. J Liposome Res. 2019; 29(3):251-263.
